Chronic myeloid leukaemia vaccine

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameChronic myeloid leukaemia vaccine
Drug Alias NameChronic myelogenous leukaemia vaccine慢性骨髓性白血病疫苗Multivalent BCR-ABL oncogene product fusion peptide vaccineAblvaxVAX-100 +[7] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsNeoplasm, ResidualLeukemia, Myelogenous, ChronicLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOhsu Knight Cancer InstituteMemorial Sloan Kettering Cancer CenterThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasm, ResidualLeukemia, Myelogenous, ChronicLeukemia

Other Information

ATC CodeN/A
Related LinksN/A